Achievable predictive biomarkers for tumor reaction to mTOR inhibitors, as happen to be explained in glioblastoma, breast and prostate cancer cells, may be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] Thus, this facts is predicated on preclinical assays, determined by in vitro cultured tumor cell strains, which propos